Note: | D.S. was supported by NWO VENI 451-08-026, BBRF (NARSAD) grant 21668, NWO Top 912-16-064. O.A.A. reports grants from the Research Council of Norway, the Kristian Gerhard Jebsen Stiftelsen, and South-Eastern Norway Regional Health Authority. D.I.B. was supported by the KNAW Royal Netherlands Academy of Science Professor Award (PAH/6635), Spinozapremie (NWO- 56-464-14192), University Research Fellow grant (URF). S.J.B. was funded by T32 DA037183 from the National Institute on Drug Abuse. B.P. and D.B.C. were supported by NIAAA-AA008401 (awarded to B.P.). T.E. was funded by the South Eastern Norway Regional Health Authority (2015-078), the Ebbe Frøland Foundation, and a research grant from Mrs. Throne-Holst. R.L.G. is supported by NIH K18DC017383, NIH DP2HD098859, NSF 1926794. J.H. was funded by T32 DA037183 from the National Institute on Drug Abuse. W.G.I. was supported by grants R37 DA005147, R01 DA036216, R37 AA009367. E.G.J. was supported by the Research Council of Norway. C.L.M. was supported by NSF DGE-1926736. S.M.M. was supported by R21AA026919. S.E.M was supported by NHMRC APP1158127 and APP1172917. J.L.M. was funded by grant numbers U10 AA008401; K01DA037914. T.M. was supported by the Norwegian Research Council. P.M.T. was funded by NIH grant U54 EB020403 from the Big Data to Knowledge (BD2K) Program. S.M.S was supported by the Epilepsy Society. E.v.D. was supported by the Dutch Organization for Health Research and Development (ZonMW) Grant 60-63600-98-711, and the Brain Center Rudolf Magnus Grant 2019. M.V. was funded by the Ministry of Science and Innovation, Spain, grant number PGC2018-099013-A-I00 and by the María de Maeztu Unit of Excellence (Institute of Neurosciences, Universitat de Barcelona) MDM-2017-0729. Brisbane Adolescent Twin Study: Funding was obtained from the Australian Research Council, grant numbers A79600334, A79906588, A79801419, DP0212016. Netherland Twin Register: Funding was obtained from the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organisation for Health Research and Development (ZonMW) grants 904-61-090, 985-10-002, 912-10-020, 904-61-193,480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction 311-60-008, 016-115-035, 481-08-011, 400-07-080, 056-32-010, Middelgroot-911-09-032, NWO Gravity program 024.001.003, NWO-Groot 480-15-001/674, Center for Medical Systems Biology (CSMB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL 184.021.007/184.033.111), X-Omics 184-034-019; Amsterdam Public Health research institute (former EMGO+); Neuroscience Amsterdam research institute (former NCA); the European Community's Fifth and Seventh Framework Program (FP5-LIFE QUALITY-CT-2002-2006, FP7-HEALTH-F4-2007-2013, grant 01254: GenomEUtwin, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council Starting 284167, Consolidator 771057, Advanced 230374; Rutgers University Cell and DNA Repository (NIMH U24 MH068457-06), the National Institutes of Health (NIH, R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01 DK092127-04, Grand Opportunity grants 1RC2 MH089951 and 1RC2 MH089995); the Avera Institute for Human Genetics, Sioux Falls, South Dakota (USA). Part of the genotyping and analyses were funded by the Genetic Association Information Network (GAIN) of the Foundation for the National Institutes of Health. Computing was supported by NWO through grant 2018/EW/00408559, BiG Grid, the Dutch e-Science Grid and SURFSARA. The LIFE cohort (LIFE—Leipzig Research Center for Civilization Diseases) is funded by means of the European Union, by the European Regional Development Fund (ERDF) and by means of the Free State of Saxony within the framework of the excellence initiative. |
---|